Articles from NICOX SA
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream
By NICOX SA · Via GlobeNewswire · December 4, 2024
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
By NICOX SA · Via GlobeNewswire · December 2, 2024
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial
By NICOX SA · Via GlobeNewswire · November 19, 2024
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
By NICOX SA · Via GlobeNewswire · October 17, 2024
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
By NICOX SA · Via GlobeNewswire · September 23, 2024
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
By NICOX SA · Via GlobeNewswire · September 4, 2024
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
By NICOX SA · Via GlobeNewswire · July 25, 2024
Nicox announces attendance at upcoming conferences
By NICOX SA · Via GlobeNewswire · July 19, 2024
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
By NICOX SA · Via GlobeNewswire · July 16, 2024
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
By NICOX SA · Via GlobeNewswire · May 24, 2024
Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
By NICOX SA · Via GlobeNewswire · May 6, 2024
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
By NICOX SA · Via GlobeNewswire · April 24, 2024
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
By NICOX SA · Via GlobeNewswire · April 22, 2024